Northwestern University Feinberg School of Medicine

Asher Center for the Study and Treatment of Depressive Disorders

Pharmacogenetic Risks Operating in Failure Of Nifedipine to Delay Preterm Birth (PROFOUND)

Pharmacogenetic Risks Operating in Failure Of Nifedipine to Delay Preterm Birth (PROFOUND)

Northwestern University IRB STU00223622

Principal Investigators: Katherine L. Wisner, MD MS (Department of Psychiatry) and Catherine Stika, MD (Department of Obstetrics and Gynecology).

Why is this research study important?

The aim of this study is to better understand how the standard dose of nifedipine works to delay preterm labor in women with a specific genetic makeup.

The drug nifedipine is given to delay preterm delivery. The amount of nifedipine in the blood may differ between women depending on their genetic makeup. If the levels are too low, nifedipine may not be able to delay labor.

In this study, we will study genetic factors that determine how much nifedipine develops in your blood. This means that when two people with different genes take the same dose, the amount of the medicine in their blood can vary dramatically. About 75% of Black women carry a gene that causes nifedipine to be broken down so rapidly that it may not be effective in delaying preterm birth.

Our overall goal is to develop individualized guidelines for an optimal dosing strategy of nifedipine.

You may be eligible to participate if you:

What’s involved?

Compensation Includes:

If you are interested in participating or would like to hear more information, please contact our research team at elizabeth.kovan1@northwestern.edu  or 312-695-7966.